Vaccines

The 2 revisions made to the EUA pertain to the number of doses allotted to the current vials containing the vaccine, and allow a new vial that has a maximum of 15 doses.

The companies are now seeking a Biologics License Application with the FDA, which would allow it to become more greatly available for adults in the US.

The pivotal phase 3 data, based off 18 reported cases among placebo patients, includes the companies' intention to request authorization for adolescents aged 12-15 years old.

Cases have increased by 16%, while 50 million have now been fully vaccinated. Federal leadership is asking Americans to hold on longer.

A statement hours after the company reported promising interim phase 3 data stated the Data Safety and Monitoring Board believes they included outdated data “which may have provided an incomplete view of the efficacy data.”

After a year of setbacks, AZD1222 has been associated with 100% prevention of severe COVID-19 in US trial participants. Could emergency authorization come soon?

Regardless of symptom status, the rate of participants positive for pan-immunoglobulins with neutralizing antibodies at baseline remained stable throughout 2020.

The new findings support increased protection from reinfection up to 6 months after first testing positive, though older patients are at greater risk of reinfection.

Researchers and clinicians continually failed to connect with the greater public on matters of the pandemic. What drove the divide between the already distanced groups?

Phase 1/2 trial results showed the immunomodulary vaccine regimen could induce significant T-cell response in patients with HIV.

The data additionally show a 94% prevention against asymptomatic SARS-CoV-2 infection, at a time when the country's dominant strain was the B.1.1.7 variant.

Though the product is authorized more than 70 countries, there is currently no reported US trial data, nor application for authorization to the FDA.

The acquisition of the Johnson & Johnson pharmaceutical company's vaccine would likely be completed in the latter half of this year.

A UK health authority representative discussed the possibility of a fall season booster to prevent another winter surge of cases.

The statement comes on the same day as a rare production agreement between pharmaceutical rivals, and Texas' announced lift of spread mitigation measures.

The new trial comes at a time when the FDA has provided guidance on navigating immunogenicity trials for vaccines designed against more transmissible SARS-CoV-2 strains.

A massive assessment of a quickly vaccinated population shows the mRNA vaccine provides greater protection over time.

A talk on optimistic, but pragmatic hopes for HIV cure and vaccine research, led by federal-level experts.

TicoVac will be decided on for both pediatric and adult people at risk of the tick-borne virus in August.

The new advisory is informed by currently-understood effect of authorized vaccines against circulating SARS-CoV-2—which show benefit nonetheless.

The news comes on the same day as new data showing the vaccine's efficacy as a single-dose prophylactic, as well as the company's application for eased storage standards for US supplies.

New South Africa-based data show not only lessened protection versus the region's dominant variant, but a reduced vaccine-induced antibody neutralization.

The two-dose vaccine's ineffective prevention of the more transmissible virus variant led to official seeking better options—and broader outcomes.

Pending advisory committee support and granted authorization, the adenovirus vaccine could become the first single-shot option in the US.

New preliminary phase 3 data show the two-dose vaccine may even hold benefit for single-dose use.